Clinical Trial Update: A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety of starting vericiguat at a 5 mg dose in participants with chronic heart failure with reduced ejection fraction; study compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Vericiguat (vericiguat)

Snippet

Sponsor: Bayer | Conditions: Chronic Heart Failure With Reduced Ejection Fraction | Phase 2 | Status: COMPLETED | Results posted: 2025-09-25